Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address Please contact the publisher to request reinstatement.
Case Report/Case Series
July 2013

Intravitreal Fasudil Combined With Bevacizumab for Persistent Diabetic Macular EdemaA Novel Treatment

Author Affiliations
  • 1Ophthalmic Research Center, Labbafinejad Medical Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran
  • 2Center for Excellence in Functional and Molecular Imaging, Brigham and Women’s Hospital, and Department of Radiology, Harvard Medical School, Boston, Massachusetts

Copyright 2013 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Restrictions Apply to Government Use.

JAMA Ophthalmol. 2013;131(7):923-924. doi:10.1001/jamaophthalmol.2013.143

Despite recent advances in pharmacotherapy for diabetic macular edema (DME), satisfying anatomical and visual results are not always achieved. Improved understanding of the mechanisms underlying diabetic retinopathy may pave the way for new treatment modalities for DME that is refractory to current therapies.

In addition to high vascular endothelial growth factor levels,1 increased activity of the Rho/ROCK pathway has recently been demonstrated in retinal vessels of diabetic rats.2 Experimental studies have demonstrated that fasudil hydrochloride, a potent ROCK inhibitor, can suppress leukocyte adhesion and prevent neutrophil-induced retinal endothelial cell damage.2

First Page Preview View Large
First page PDF preview
First page PDF preview